SLP dividend history
Simulations Plus Inc. (SLP) dividend declarations and ex-dividend dates - real-time wire coverage of every payout disclosure.
Recent dividend items
- Simulations Plus Announces Cash DividendBoard of Directors announces quarterly dividend of $0.06 per share Simulations Plus, Inc. (NASDAQ:SLP) announced today that the Company's Board of Directors has declared a cash dividend of $0.06 per share of the Company's common stock, payable on November 7, 2022, to shareholders of record as of October 31, 2022. The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors. About Simulations Plus Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supportin
- Simulations Plus Announces Cash DividendBoard of Directors announces quarterly dividend of $0.06 per share Simulations Plus, Inc. (NASDAQ:SLP) announced today that the Company's Board of Directors has declared a cash dividend of $0.06 per share of the Company's common stock, payable on November 1, 2021, to shareholders of record as of October 25, 2021. The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors. About Simulations Plus, Inc. Serving clients worldwide for 25 years, Simulations Plus, Inc. is a leading provider of modeling and simulation software and consulting services supporting drug di
- Simulations Plus Enters New Funded Collaboration to Improve Lung Exposure Models for Pulmonary Infection TreatmentsLANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to develop machine learning models and enhance physiologically based pharmacokinetics / pharmacodynamics (PBPK/PD) approaches for potential treatments of pulmonary infections. “Significant investments have been made by our partner to identify new oral and/or intravenous therapies for the lung, which will make our technology a centerpiece of their research strategy and ena